Moderna’s Omicron Booster Strategy Lifts Biotechnology ETFs

Moderna (NasdaqGS: MRNA) jumped on Monday after announcing that a higher dosage booster of its vaccine could help mitigate COVID-19 Omicron risks before a tailor-made shot is finalized, lifting biotechnology sector-related exchange traded funds. On Monday, the Invesco Nasdaq Biotechnology ETF...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.